Baxter’s infusion pumps are in the crosshairs once again after cybersecurity software developer Rapid7 discovered multiple potential vulnerabilities in the devices.

EZH2 inhibitors are a budding drug class—already with one approved therapy and a few in the pipeline—and Pfizer is the largest pharma to add the tool to its clinical belt. And phase 1 data of Pfizer’s asset point toward a positive safety profile, with glimpses of benefit for some cancer patients, though not all tested may be able to count on the therapy.

Four months after the latest trial failure for Roche’s tiragolumab, GSK is still pushing ahead with its own anti-TIGIT inhibitor, bullish that plenty of opportunities remain for the next-gen therapy.

The European Society for Medical Oncology (ESMO) congress could have been a victory lap for Bristol Myers Squibb and Nektar Therapeutics, the moment when a bold bet delivered clinical data to upend the immuno-oncology space. Instead, the partners were left to sift through the wreckage of a failed trial that suggested bempegaldesleukin may make Opdivo less—not more—effective.

New phase 2b findings show an investigational malaria vaccine booster from the University of Oxford maintained high efficacy levels a year after the initial three-shot regimen—a feat in a disease area that scientists have long struggled to develop effective vaccines and therapies.

Using what was once a lesser-known regulatory option made world-famous by the COVID-19 pandemic, the FDA has granted its first Emergency Use Authorization to a diagnostic test for monkeypox as cases continue to spread worldwide.

VistaGen Therapeutics has been given the all-clear to continue a phase 3 trial of its social anxiety nose spray after the biotech paused enrollment following poor results from a similar late-stage study.

LifeArc Ventures’ billion-pound investment strategy appears to be paying off, as the British life sciences VC fund saw its first portfolio company sold off in the form of Ducentis BioTherapeutics.

Medical device startups are tasked with quite the balancing act: They’re developing new products while simultaneously fundraising to support that development and working with regulatory agencies to bring the products to market.

It’s a good day to be the CFO of SpringWorks Therapeutics. The precision medicine biotech has not only secured $225 million in funding, but also banked a further $75 million equity investment as part of an expanded agreement with GSK.